Prange Karen Insider Trading Activity

Average Profitability
<0.0001%
Insider Buys Quantity
0
Insider Buys Sum
$0
Insider Sells Quantity
8
Insider Sells Sum
$1.24M

Insider Activity of Prange Karen

According to the SEC Form 4 filings, Prange Karen, being in a position of

  1. director at AtriCure, Inc.,
    оver the last 12 months, has bought 0 shares, and sold 6564 shares for $224,233,
    over all time since 2023-06-08, has bought 0 shares, and sold 13377 shares for $490,911.

Biography of Prange Karen

No biography is available at this moment.

Statistics of Insider Transactions Last Year

Amount of Insider Buys and Sells by Stocks

Buys
 $000
Sells
 $224,2332100

Comparison of Insiders on Amount of Buys and Sells

2026-08-05SaleAtriCure, Inc.
ATRC
director
3,564
0.0069%
$38.80$138,283+41.15%
2026-05-20SaleAtriCure, Inc.
ATRC
director
3,000
0.0059%
$28.65$85,950+50.21%
2025-03-05SaleAtriCure, Inc.
ATRC
director
6,100
0.0124%
$38.12$232,532-8.67%
2023-06-08SaleAtriCure, Inc.
ATRC
director
713
0.0015%
$47.89$34,146-25.7%
2016-03-08SaleBoston Scientific Corporation
BSX
SVP&Pres, Uro & Pelvic Health
14,747
0.0011%
$17.27$254,749+31.76%
2016-02-08SaleBoston Scientific Corporation
BSX
SVP&Pres, Uro & Pelvic Health
6,216
0.0005%
$16.05$99,785+39.33%
2015-07-07SaleBoston Scientific Corporation
BSX
SVP&Pres, Uro & Pelvic Health
17,456
0.0013%
$17.66$308,308+0.56%
2015-03-03SaleBoston Scientific Corporation
BSX
SVP&Pres, Uro & Pelvic Health
2,492
0.0002%
$16.79$41,838+4.95%
2015-02-27SaleBoston Scientific Corporation
BSX
SVP&Pres, Uro & Pelvic Health
1,307
<0.0001%
$16.80$21,963+4.14%
2014-12-10SaleBoston Scientific Corporation
BSX
SVP&Pres, Uro & Pelvic Health
19,753
0.0015%
$12.64$249,607+37.58%
Total: 10
Company
About Prismo.proIdeasArticlesPrivacy PolicyTerms of ServiceContact Us
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny Stocks
Stock Tools
Insiders ScreenerStocks ScreenerTop StocksStock NewsInsider RatioList of All Stocks
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.